(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 17.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 15.14%.
Niagen Bioscience's revenue in 2026 is $129,423,000.On average, 7 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,075,336,786, with the lowest NAGE revenue forecast at $11,300,958,467, and the highest NAGE revenue forecast at $13,058,725,178. On average, 6 Wall Street analysts forecast NAGE's revenue for 2027 to be $13,835,505,912, with the lowest NAGE revenue forecast at $12,792,057,153, and the highest NAGE revenue forecast at $14,653,127,694.
In 2028, NAGE is forecast to generate $17,156,443,749 in revenue, with the lowest revenue forecast at $16,483,767,650 and the highest revenue forecast at $17,660,950,824.